Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Jun;204(6):2324-2331.
doi: 10.1111/bjh.19410. Epub 2024 Mar 17.

Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia

Thomas Bauch  1 , Georg Hempel  1
Affiliations
Clinical Trial

Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia

Thomas Bauch et al. Br J Haematol. 2024 Jun.

Abstract

Physiologically based pharmacokinetic (PBPK) modelling is an alternative modelling technique that is increasingly used in pharmacokinetics. Due to its nature, it can be complementarily employed to population pharmacokinetics, especially when it comes to small population size. Here, we report the proof of concept of its application to accurately describe the pharmacokinetics of a recombinant L-asparaginase in paediatric patients with acute lymphoblastic leukaemia. Data from two randomized, double-blind, phase II/III clinical studies (MC-ASP.4/ALL; MC-ASP.5/ALL) were included to setup and evaluate the final model, respectively. Final population values for basic pharmacokinetic parameters were calculated (clearance: 0.0569 L/h/19.5 kg, volume of distribution: 1.251 L, half-life: 18.5 h, trough concentration: 140.9 IU/L). Pharmacokinetic parameter prediction as well as predictive performance of the model proofed to be comparable to a separately developed population pharmacokinetic model with 13% deviation in predicted median L-asparaginase trough levels. To the best of our knowledge, this is the first whole-body PBPK model of a non-antibody therapeutic protein.

Keywords: L‐asparaginase; acute leukaemia; mathematical modelling; paediatric haematology; pharmacokinetics.

PubMed Disclaimer

References

REFERENCES

    1. Andersen ME, MacNaughton MG, Clewell HJ III, Paustenbach DJ. Adjusting exposure limits for long and short exposure periods using a physiological pharmacokinetic model. Am Ind Hyg Assoc J. 1987;48(4):335–343. https://doi.org/10.1080/15298668791384850
    1. Paustenbach DJ, Clewell HJ III, Gargas ML, Andersen ME. A physiologically based pharmacokinetic model for inhaled carbon tetrachloride. Toxicol Appl Pharmacol. 1988;96(2):191–211. https://doi.org/10.1016/0041‐008x(88)90080‐4
    1. Glassman PM, Balthasar JP. Physiologically‐based modeling of monoclonal antibody pharmacokinetics in drug discovery and development. Drug Metab Pharmacokinet. 2019;34(1):3–13. https://doi.org/10.1016/j.dmpk.2018.11.002
    1. Brookhuis SAM, Allegaert K, Hanff LM, Lub‐de Hooge MN, Dallmann A, Mian P. Modelling tools to characterize acetaminophen pharmacokinetics in the pregnant population. Pharmaceutics. 2021;13(8):1302. https://doi.org/10.3390/pharmaceutics13081302
    1. Ginsberg G, Hattis D, Russ A, Sonawane B. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents. J Toxicol Environ Health A. 2004;67(4):297–329. https://doi.org/10.1080/15287390490273550

Publication types

LinkOut - more resources